BR112018011177A2 - conjugados de citarabina para terapia de câncer - Google Patents
conjugados de citarabina para terapia de câncerInfo
- Publication number
- BR112018011177A2 BR112018011177A2 BR112018011177A BR112018011177A BR112018011177A2 BR 112018011177 A2 BR112018011177 A2 BR 112018011177A2 BR 112018011177 A BR112018011177 A BR 112018011177A BR 112018011177 A BR112018011177 A BR 112018011177A BR 112018011177 A2 BR112018011177 A2 BR 112018011177A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer therapy
- cytarabine
- conjugates
- cytarabine conjugates
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262428P | 2015-12-03 | 2015-12-03 | |
| PCT/IL2016/050077 WO2017093993A1 (en) | 2015-12-03 | 2016-01-25 | Cytarabine conjugates for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018011177A2 true BR112018011177A2 (pt) | 2018-11-21 |
Family
ID=58796462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018011177A BR112018011177A2 (pt) | 2015-12-03 | 2016-01-25 | conjugados de citarabina para terapia de câncer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11058701B2 (enExample) |
| EP (1) | EP3383407B1 (enExample) |
| JP (3) | JP7149183B2 (enExample) |
| CN (1) | CN108289905A (enExample) |
| AU (2) | AU2016362830B2 (enExample) |
| BR (1) | BR112018011177A2 (enExample) |
| CA (1) | CA3007058C (enExample) |
| IL (2) | IL259631B (enExample) |
| RU (1) | RU2708672C1 (enExample) |
| WO (1) | WO2017093993A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| IL259569B2 (en) | 2015-12-03 | 2024-03-01 | Biosight Ltd | Salts of cytarabine-amino acids conjugates |
| IL271946B (en) * | 2017-07-09 | 2022-09-01 | Biosight Ltd | Combination cancer therapy |
| CN110590862A (zh) * | 2019-11-01 | 2019-12-20 | 南京师范大学 | 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用 |
| KR20220137028A (ko) * | 2020-02-04 | 2022-10-11 | 바이오사이트 리미티드 | 아스파시타라빈 약제학적 조성물 및 이의 용도 |
| WO2021214772A1 (en) * | 2020-04-23 | 2021-10-28 | Biosight Ltd. | Methods and regimens for the treatment of hematological cancer |
| EP4213858A1 (en) * | 2020-09-21 | 2023-07-26 | BioSight Ltd. | Crystalline form of aspacytarabine |
| CN112409431B (zh) * | 2020-12-07 | 2023-04-21 | 武汉伯瑞恒医药科技有限公司 | 阿糖胞苷结构类似物及其制备方法和用途 |
| WO2023089617A1 (en) * | 2021-11-21 | 2023-05-25 | Biosight Ltd. | Cytarabine-amino acid based prodrug for the treatment of cancer |
| WO2023175622A1 (en) * | 2022-03-17 | 2023-09-21 | Biosight Ltd. | Crystalline forms of aspacytarabine |
| WO2023228177A1 (en) * | 2022-05-22 | 2023-11-30 | Biosight Ltd. | Compositions comprising aspacytarabine and additional compounds, and use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2949451A (en) | 1959-04-21 | 1960-08-16 | Hoffmann La Roche | Preparation of thymidine and deoxyfluorouridine, and intermediates therefor |
| US3041335A (en) | 1959-04-21 | 1962-06-26 | Hoffmann La Roche | Mercury salts of nitrogen heterocyclics and preparation thereof |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4296105A (en) | 1978-08-03 | 1981-10-20 | Institut International De Pathologie Cellulaire Et Moleculaire | Derivatives of doxorubicine, their preparation and use |
| US4348522A (en) | 1980-01-23 | 1982-09-07 | Starks Associates, Inc. | N-(phosphonacetyl)-L-aspartic acid salts with piperazine, cyclohexylamine and calcium |
| EP0329184A3 (en) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
| RU2085557C1 (ru) | 1991-09-30 | 1997-07-27 | Санкио Компани Лимитед | Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения |
| US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| EP0737077A1 (en) * | 1994-01-11 | 1996-10-16 | Targetech, Inc. | Hepatocyte-targeted drug conjugates |
| WO1996005863A1 (fr) | 1994-08-19 | 1996-02-29 | La Region Wallonne | Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation |
| JPH0859688A (ja) | 1994-08-25 | 1996-03-05 | Mitsui Toatsu Chem Inc | ５’−チオノエステル置換トリフルオロチミジン誘導体およびそれを有効成分とする制癌剤 |
| WO1997036480A1 (en) | 1996-03-29 | 1997-10-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| PT1144011E (pt) | 1998-12-11 | 2010-06-16 | Coulter Pharm Inc | Compostos pró-fármacos e processo para a sua preparação |
| BR0315795A (pt) | 2002-10-31 | 2005-09-13 | Metabasis Therapeutics Inc | Pró-medicamentos de monofosfato de citarabina |
| EP1718145A4 (en) | 2004-02-02 | 2012-03-07 | Biosight Ltd | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS |
| EP2099316B1 (en) | 2006-12-13 | 2017-06-21 | Givaudan S.A. | Flavour modulating derivative of a carboxylic acid and a purine, pyrimidine, nucleoside or nucleotide |
| CN101812105A (zh) | 2009-02-25 | 2010-08-25 | 沈阳药科大学 | 阿糖胞苷5’-o-氨基酸酯和其盐类及其制备方法 |
| JP5873656B2 (ja) * | 2011-06-13 | 2016-03-01 | 株式会社Ihi | 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤 |
| JPWO2013058294A1 (ja) | 2011-10-18 | 2015-04-02 | 味の素株式会社 | 膵臓癌及び／又は胆道癌治療薬 |
| US20150328245A1 (en) | 2012-12-18 | 2015-11-19 | Godavari Biorefineries Limited | Agents for Eliminating Tumour-Initiating Cells |
| WO2015178265A1 (ja) | 2014-05-23 | 2015-11-26 | 日本化薬株式会社 | 新規なグルタミン酸誘導体およびその用途 |
-
2016
- 2016-01-25 JP JP2018527797A patent/JP7149183B2/ja active Active
- 2016-01-25 RU RU2018119319A patent/RU2708672C1/ru active
- 2016-01-25 BR BR112018011177A patent/BR112018011177A2/pt not_active Application Discontinuation
- 2016-01-25 US US15/780,732 patent/US11058701B2/en active Active - Reinstated
- 2016-01-25 CA CA3007058A patent/CA3007058C/en active Active
- 2016-01-25 AU AU2016362830A patent/AU2016362830B2/en not_active Ceased
- 2016-01-25 WO PCT/IL2016/050077 patent/WO2017093993A1/en not_active Ceased
- 2016-01-25 CN CN201680070972.5A patent/CN108289905A/zh active Pending
- 2016-01-25 EP EP16870114.2A patent/EP3383407B1/en active Active
-
2018
- 2018-05-27 IL IL259631A patent/IL259631B/en unknown
-
2020
- 2020-07-17 JP JP2020122708A patent/JP2020183419A/ja active Pending
-
2021
- 2021-10-27 IL IL287644A patent/IL287644A/en unknown
-
2022
- 2022-05-10 JP JP2022077787A patent/JP7417658B2/ja active Active
- 2022-06-22 AU AU2022204373A patent/AU2022204373B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN108289905A (zh) | 2018-07-17 |
| JP2018535989A (ja) | 2018-12-06 |
| JP2022097619A (ja) | 2022-06-30 |
| JP2020183419A (ja) | 2020-11-12 |
| EP3383407A4 (en) | 2019-07-17 |
| IL259631A (en) | 2018-07-31 |
| US20180369265A1 (en) | 2018-12-27 |
| AU2016362830A1 (en) | 2018-07-12 |
| CA3007058A1 (en) | 2017-06-08 |
| JP7149183B2 (ja) | 2022-10-06 |
| IL259631B (en) | 2021-10-31 |
| JP7417658B2 (ja) | 2024-01-18 |
| CA3007058C (en) | 2023-10-17 |
| RU2708672C1 (ru) | 2019-12-11 |
| US11058701B2 (en) | 2021-07-13 |
| AU2022204373A1 (en) | 2022-07-28 |
| AU2022204373B2 (en) | 2024-01-25 |
| WO2017093993A1 (en) | 2017-06-08 |
| IL287644A (en) | 2021-12-01 |
| EP3383407A1 (en) | 2018-10-10 |
| EP3383407B1 (en) | 2023-12-06 |
| AU2016362830B2 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018011177A2 (pt) | conjugados de citarabina para terapia de câncer | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
| BR112016024789A2 (pt) | métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2019011148A (es) | Metodos de tratamiento. | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
| EA201890754A1 (ru) | Соединения и способы их применения | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| NZ756730A (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
| EP3581182A4 (en) | DRUG COMBINATION FOR THE TREATMENT OF PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| WO2012103457A3 (en) | Stilbene analogs and methods of treating cancer | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
| AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
| BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |